scholarly journals The Crosstalk between Myeloid Derived Suppressor Cells and Immune Cells: To Establish Immune Tolerance in Transplantation

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Chao Zhang ◽  
Shuo Wang ◽  
Cheng Yang ◽  
Ruiming Rong
Keyword(s):  
T Cells ◽  
Natural Killer ◽  
Immune Cells ◽  
Tolerance Induction ◽  
Suppressor Cells ◽  
Immunosuppressive Drugs ◽  
Myeloid Derived Suppressor Cells ◽  
Immune Tolerant ◽  
Killer T Cells

Myeloid derived suppressor cells (MDSCs) are a heterogeneous population of myeloid precursor and progenitor cells and endowed with a robust immunosuppressive activity in multiple pathophysiological conditions. Recent studies have uncovered the crosstalk between MDSCs and immune cells (i.e., natural killer cells, dendritic cells, macrophages, natural killer T cells, and regulatory T cells) and its role in the establishment and maintenance of immune tolerant microenvironment in transplantation. Considering their strong immunosuppressive capability, MDSCs could become a prospective clinical regimen during transplantation tolerance induction, resulting in long-term graft survival with decreased or without immunosuppressive drugs. The review summarized recent research advances in this field and looked ahead at the research directions in the future.

scholarly journals The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells

Immunology ◽  
2013 ◽  
Vol 138 (2) ◽  
pp. 105-115 ◽  
Author(s):  
Dennis Lindau ◽  
Paul Gielen ◽  
Michiel Kroesen ◽  
Pieter Wesseling ◽  
Gosse J. Adema
Keyword(s):  
T Cells ◽  
Regulatory T Cells ◽  
Natural Killer ◽  
Suppressor Cells ◽  
Natural Killer T Cells ◽  
Myeloid Derived Suppressor Cells ◽  
Killer T Cells ◽  
Natural Killer T

scholarly journals Myeloid-derived suppressor cells at diagnosis may discriminate between benign and malignant ovarian tumors

2019 ◽  
Vol 29 (9) ◽  
pp. 1381-1388 ◽  
Author(s):  
An Coosemans ◽  
Thaïs Baert ◽  
Jolien Ceusters ◽  
Pieter Busschaert ◽  
Chiara Landolfo ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
T Cells ◽  
Immune System ◽  
Natural Killer Cells ◽  
Regulatory T Cells ◽  
Natural Killer ◽  
Immune Cells ◽  
Suppressor Cells ◽  
Myeloid Derived Suppressor Cells ◽  
Killer Cells

BackgroundThe behavior of the immune system as a driver in the progression of ovarian cancer has barely been studied. Our knowledge is mainly limited to the intra-tumoral adaptive immune system. Because of the widespread metastases of ovarian cancer, an assessment of the circulating immune system seems more accurate.To demonstrate the presence of immune cells in blood samples of patients with ovarian neoplasms.MethodsIn this exploratory prospective cohort study, peripheral blood mononuclear cells were collected at diagnosis from 143 women, including 62 patients with benign cysts, 13 with borderline tumor, 41 with invasive ovarian cancer, and 27 age-matched healthy controls. Immune profile analyses, based on the presence of CD4 (cluster of differentiation), CD8, natural killer cells, myeloid-derived suppressor cells, and regulatory T cells, were performed by fluorescence activated cell sorting.ResultsIn a multivariable analysis, six immune cells (activated regulatory T cells, natural killer cells, myeloid-derived suppressor cells, monocytic myeloid-derived suppressor cells, exhausted monocytic myeloid-derived suppressor cells, and total myeloid cells) were selected as independent predictors of malignancy, with an optimism-corrected area under the receiver operating characteristic curve (AUC) of 0.858. In contrast, a profile based on CD8 and regulatory T cells, the current standard in ovarian cancer immunology, resulted in an AUC of 0.639.ConclusionsOur immune profile in blood suggests an involvement of innate immunosuppression driven by myeloid-derived suppressor cells in the development of ovarian cancer. This finding could contribute to clinical management of patients and in selection of immunotherapy.

scholarly journals Myeloid-Derived Suppressor Cells as a Regulator of Immunity in Organ Transplantation

2018 ◽  
Vol 19 (8) ◽  
pp. 2357 ◽  
Author(s):  
Tsukasa Nakamura ◽  
Hidetaka Ushigome
Keyword(s):  
T Cells ◽  
Organ Transplantation ◽  
Allograft Rejection ◽  
Current Knowledge ◽  
Suppressor Cells ◽  
Regulatory Function ◽  
Myeloid Derived Suppressor Cells ◽  
Killer T Cells ◽  
Shed Light

Regulation of allo-immune responses is proposed as a topic for investigation in the current field of organ transplantation. As a regulator, regulatory T cells (Tregs) have received attention due to their ability to control allograft rejection. Concurrently, however, the independent action of Tregs is not enough to achieve tolerance status in many situations. Meanwhile, as a multi-functional regulator, myeloid-derived suppressor cells (MDSCs) can suppress effector T cells as well as induce Tregs or regulatory B cells (Bregs) in certain circumstances. Furthermore, the importance of a crosstalk between MDSCs and natural killer T cells to induce tolerance has been reported. Thus, orchestration between MDSCs, myeloid regulators, T/Bregs and other lymphoid/myeloid regulators can shed light on achieving allogeneic tolerance. Here, we review the current knowledge in terms of immunological regulatory function displayed by MDSCs in the context of organ transplantation. Ideal control of MDSCs would lead to a reduction of allograft rejection and subsequent long-term allograft acceptance.

scholarly journals β-Mannosylceramide Activates Type I Natural Killer T Cells to Induce Tumor Immunity without Inducing Long-Term Functional Anergy

2013 ◽  
Vol 19 (16) ◽  
pp. 4404-4411 ◽  
Author(s):  
Jessica J. O'Konek ◽  
Shingo Kato ◽  
Satomi Takao ◽  
Liat Izhak ◽  
Zheng Xia ◽  
...  
Keyword(s):  
T Cells ◽  
Natural Killer ◽  
Tumor Immunity ◽  
Natural Killer T Cells ◽  
Type I ◽  
Killer T Cells ◽  
Natural Killer T

F.35. Long-Term IFN-γ Dependent Efficacy of Activated Vα14I Natural Killer T-Cells in the Prevention of Collagen-Induced Arthritis

2006 ◽  
Vol 119 ◽  
pp. S62-S63
Author(s):  
Ken Coppieters ◽  
Katrien Van Beneden ◽  
Ann Vervloet ◽  
Pieter Dewint ◽  
Peggy Jacques ◽  
...  
Keyword(s):  
T Cells ◽  
Natural Killer ◽  
Natural Killer T Cells ◽  
Collagen Induced Arthritis ◽  
Ifn Γ ◽  
Killer T Cells ◽  
Natural Killer T

scholarly journals Treg Therapies Revisited: Tolerance Beyond Deletion

2021 ◽  
Vol 11 ◽  
Author(s):  
Nina Pilat ◽  
Jonathan Sprent
Keyword(s):  
T Cells ◽  
Immune Tolerance ◽  
Therapeutic Potential ◽  
Tolerance Induction ◽  
Allogeneic Transplantation ◽  
Immunosuppressive Drugs ◽  
Long Term Results ◽  
Inflammatory Reactions

Induction of immune tolerance is the Holy Grail in transplantation medicine and autoimmunity. Currently, patients are required to use immunosuppressive drugs for the rest of their lives, resulting in unwanted side effects and complication from global suppression of the immune response. It is well established that regulatory T cells (Tregs) are critical for the maintenance of immune tolerance towards self-antigens by several mechanisms of immune regulation, in parallel with intrathymic deletion of self-reactive T cells during ontogeny. Therefore, approaches for increasing Treg numbers or function in vivo could provide an all-purpose solution for tolerance induction. Currently, most state-of-the-art therapeutics for treating autoimmune diseases or preventing allograft rejection work either by general immunosuppression or blocking inflammatory reactions and are non-specific. Hence, these approaches cannot provide satisfactory long-term results, let alone a cure. However, in animal models the therapeutic potential of Treg expansion for inducing effective tolerance has now been demonstrated in various models of autoimmunity and allogeneic transplantation. Here, we focus on therapies for increasing the size of the Treg pool by expanding endogenous Treg numbers in vivo or by adoptive transfer of Tregs. In particular, we discuss IL-2 based approaches (low dose IL-2, IL-2 complexes) for inducing Treg expansion in vivo as well as cell-based approaches (polyclonal, antigen specific, or cell engineered) for adoptive Treg therapy. We also mention new questions arising from the first clinical studies on Treg therapy in the fields of transplantation and autoimmunity.

scholarly journals Immunosuppressive B cells expressing PD-1/PD-L1 in solid tumors: A mini review

QJM ◽  
2019 ◽  
Author(s):  
Xiaowen Sun ◽  
Tingyou Zhang ◽  
Mengqian Li ◽  
Limei Yin ◽  
Jianxin Xue
Keyword(s):  
T Cells ◽  
Cell Death ◽  
B Cells ◽  
Solid Tumors ◽  
Immune Cells ◽  
Suppressor Cells ◽  
Diagnostic Tools ◽  
Myeloid Derived Suppressor Cells ◽  
Programmed Cell Death 1 ◽  
B Cell Subsets

Abstract Expression of Programmed Cell Death-1 (PD-1/CD279) on T cells and the ligand of PD-1, PD-L1 (CD274/B7-H1) on tumor cells or other immune cells, such as myeloid-derived suppressor cells, are important mechanisms to induce malignant immunosuppression. PD-1/PD-L1 expression on B cell subsets, as well as their signaling and inhibitory functions in solid tumors will be discussed in this review with the focus on how B cells expressing PD-1/PD-L1 play immunosuppressive roles in tumor progression, aiming to figure out the potential for development of diagnostic tools and new therapies involving this unique group of cells.

CD1d-Restricted Natural Killer T Cells Are Preserved in Indian Long-Term Nonprogressors

2017 ◽  
Vol 75 (4) ◽  
pp. e104-e112 ◽  
Author(s):  
Dharmendra Singh ◽  
Manisha Ghate ◽  
Sheela Godbole ◽  
Smita Kulkarni ◽  
Madhuri Thakar
Keyword(s):  
T Cells ◽  
Natural Killer ◽  
Natural Killer T Cells ◽  
Killer T Cells ◽  
Natural Killer T
Sign in / Sign up

Export Citation Format

Share Document